β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N
A compound of the structure: or a pharmaceutically acceptable salt or composition thereof for the treatment of a host infected with or exposed to an HCV virus or other disorders more fully described herein.
1. A compound of the formula
or a pharmaceutically acceptable salt thereof.
2. A pharmaceutical composition comprising an effective therapeutic amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof, in a pharmaceutically acceptable carrier.
3. The pharmaceutical composition of claim 2 , in an oral dosage form.
4. The pharmaceutical composition of claim 3 , wherein the oral dosage form is a solid dosage form.
5. The pharmaceutical composition of claim 4 , wherein the solid dosage form is a tablet.
6. The pharmaceutical composition of claim 4 , wherein the solid dosage form is a capsule.
7. The pharmaceutical composition of claim 3 , wherein the oral dosage form is a liquid dosage form.
8. The pharmaceutical composition of claim 7 , wherein the liquid dosage form is a suspension or solution.
9. The pharmaceutical composition of claim 2 , in an intravenous formulation.
10. The pharmaceutical composition of claim 2 , in a parenteral formulation.
11. A compound of the formula
or a pharmaceutically acceptable salt thereof.
12. A pharmaceutical composition comprising an effective therapeutic amount of a compound of claim 11 or a pharmaceutically acceptable salt thereof, in a pharmaceutically acceptable carrier.
13. The pharmaceutical composition of claim 12 , in an oral dosage form.
14. The pharmaceutical composition of claim 13 , wherein the oral dosage form is a solid dosage form.
15. The pharmaceutical composition of claim 14 , wherein the solid dosage form is a tablet.
16. The pharmaceutical composition of claim 14 , wherein the solid dosage form is a capsule.
17. The pharmaceutical composition of claim 13 , wherein the oral dosage form is a liquid dosage form.
18. The pharmaceutical composition of claim 17 , wherein the liquid dosage form is a suspension or solution.
19. The pharmaceutical composition of claim 12 , in an intravenous formulation.
20. The pharmaceutical composition of claim 12 , in a parenteral formulation.
21. A compound of the formula:
or a pharmaceutically acceptable salt thereof, wherein the compound is at least 90% free of the opposite phosphorus R-enantiomer.
22. The compound of claim 21 , wherein the compound is at least 98% free of the opposite phosphorus R-enantiomer.
23. The compound of claim 21 , wherein the compound is at least 99% free of the opposite phosphorus R-enantiomer.
24. A pharmaceutical composition comprising an effective therapeutic amount of a compound of the formula
or a pharmaceutically acceptable salt thereof in a pharmaceutically acceptable carrier, wherein the compound is at least 90% free of the opposite phosphorus R-enantiomer.
25. The pharmaceutical composition of claim 24 , wherein the compound is at least 98% free of the opposite phosphorus R-enantiomer.
26. The pharmaceutical composition of claim 24 , wherein the compound is at least 99% free of the opposite phosphorus R-enantiomer.
27. The pharmaceutical composition of claim 24 , in an oral dosage form.
28. The pharmaceutical composition of claim 27 , wherein the oral dosage form is a solid dosage form.
29. The pharmaceutical composition of claim 28 , wherein the solid dosage form is a tablet.
30. The pharmaceutical composition of claim 28 , wherein the solid dosage form is a capsule.
31. The pharmaceutical composition of claim 27 , wherein the oral dosage form is a liquid dosage form.
32. The pharmaceutical composition of claim 31 , wherein the liquid dosage form is a suspension or solution.
33. The pharmaceutical composition of claim 24 , in an intravenous formulation.
34. The pharmaceutical composition of claim 24 , in a parenteral formulation.